Breaking News: A Game-Changing Treatment for Endometrial Cancer Emerges. But here's where it gets controversial... Can this new combination therapy really be the future of cancer care?
A recent analysis of the phase 3 RUBY trial has revealed promising results for patients with primary advanced or recurrent endometrial cancer. The combination of dostarlimab plus carboplatin-paclitaxel (DOST+CP) has shown significant improvement in time to first subsequent therapy (TFST) and second subsequent therapy (TSST) compared to the placebo group.
Presented at JADPRO Live 2025, the study analyzed data from patients with primary advanced stage III or IV endometrial cancer, or their first recurrent endometrial cancer. The results showed that DOST+CP not only improved progression-free survival (PFS) and overall survival (OS), but also prolonged TFST and TSST in all patient populations.
In the overall patient population, TFST was 5.1 months longer with DOST+CP, while in the mismatch repair proficient/microsatellite stable (MMRp/MSS) population, it was 2.5 months longer. The mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) population saw even more promising results, with median TFST not reached in patients assigned to receive DOST+CP.
These findings have led researchers to conclude that DOST+CP should be considered a standard of care for patients with primary advanced or recurrent endometrial cancer. But what do you think? Should this new combination therapy be the new gold standard for endometrial cancer treatment? Share your thoughts in the comments below.
